┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-06 00:16 UTC APPEARANCES ......... 3 ANNOTATIONS KNOWN ALIASES ....... 2 └──────────────────────────────────────────────────────────────┘
BMJ (British Medical Journal)
ALSO APPEARS AS
- BMJ
- BMJ (British Medical Journal)
APPEARS IN THE MARGINS OF
- Medical Guidance on Paroxetine for Adolescents and Study 329 Reference (2001-2015)
Following the 2001 publication of Study 329, an influential clinical trial on the antidepressant paroxetine (Paxil/Seroxat) for adolescent depression, questions arose regarding its efficacy and safety…
- Pharmaceutical Company Contractual Suppression of Negative Trial Results
Concerns have emerged regarding the influence of pharmaceutical industry sponsorship on clinical research, particularly the potential for contractual clauses to suppress or delay the publication of un…
- Study 329's Impact on Adolescent Antidepressant Prescriptions
Study 329, a clinical trial evaluating paroxetine and imipramine for adolescent major depression, was originally published in 2001, claiming efficacy and safety for paroxetine [1]. This original publi…